Apolipoprotein e polymorphism and the progression of diabetic nephropathy in type 2 diabetes

American Journal of Nephrology

Volumn 33, Issue 3, 2011, Pages 231-238

  Tien, Kai Jen ^a   Tu, Shih Te ^b   Chou, Chien Wen ^a   Yang, Chwen Yi ^a   Hsiao, Jeng Yueh ^c   Shin, Shyi Jang ^c   Chen, Hung Chun ^c   Hsieh, Ming Chia ^b,d  

^a CHI MEI MEDICAL CENTER   (Taiwan)

^b CHANGHUA CHRISTIAN HOSPITAL   (Taiwan)

^c KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^d CHINA MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Apolipoprotein E polymorphism; Diabetic nephropathy, Taiwan; Type 2 diabetes

Indexed keywords

ALBUMIN; APOLIPOPROTEIN E2; APOLIPOPROTEIN E3; APOLIPOPROTEIN E4; CREATININE; DIURETIC AGENT; HEMOGLOBIN A1C;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE URINE LEVEL; DIABETIC NEPHROPATHY; DIABETIC PATIENT; DISEASE COURSE; DNA POLYMORPHISM; DRUG USE; FEMALE; FOLLOW UP; GENE FREQUENCY; HEMOGLOBIN BLOOD LEVEL; HUMAN; MACROALBUMINURIA; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; PROTEIN URINE LEVEL; PROTEINURIA; TAIWAN;

APOLIPOPROTEINS E; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; POLYMORPHISM, GENETIC; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES;

EID: 79951858399     PISSN: 02508095     EISSN: None     Source Type: Journal    
DOI: 10.1159/000324561     Document Type: Article

References (30)

1. Yang WC, Hwang SJ: Incidence, prevalence and mortality trends of dialysis end-stage re-nal disease in Taiwan from 1990 to 2001: the impact of national health insurance. Nephrol Dial Transplant 2008; 23: 3977-3982.
2. Parving HH, Tarnow L, Rossing P: Genetics of diabetic nephropathy. J Am Soc Nephrol 1996; 7: 2509-2517. (Pubitemid 27469556)
3. Tien KJ, Hsiao JY, Hsu SC, Liang HT, Lin SR, Chen HC, Hsieh MC: Gender-dependent ef-fect of ACE I/D and AGT M235T polymor-phisms on the progression of urinary albu-min excretion in Taiwanese with type 2 dia-betes. Am J Nephrol 2009; 29: 299-308.
4. Hovind P, Rossing P, Tarnow L, Smidt UM, Parving HH: Progression of diabetic ne-phropathy. Kidney Int 2001; 59: 702-709.
5. Lehtinen S, Rantalaiho V, Wirta O, Paster-nack A, Laippala P, Koivula T, Lehtimaki T: Apolipoprotein E gene polymorphism, hy-percholesterolemia and glomerular filtra-tion rate in type 2 diabetic subjects: a 9-year follow-up study. J Biomed Sci 2003; 10: 260-265. (Pubitemid 36302407)
6. Pettitt DJ, Saad MF, Bennett PH, Nelson RG, Knowler WC: Familial predisposition to re-nal disease in two generations of Pima Indi-ans with type 2 (non-insulin-dependent) di-abetes mellitus. Am J Nephrol 2009; 29: 299-308.
7. Diamond JR, Karnovsky MJ: Focal and seg-mental glomerulosclerosis: analogies to ath-erosclerosis. Kidney Int 1988; 33: 917-924.
8. Mulec H, Johnson SA, Bjorck S: Relation be-tween serum cholesterol and diabetic ne-phropathy. Lancet 1990; 335: 1537-1538. (Pubitemid 20224964)
9. Kasiske BL, O'Donnell MP, Cleary MP, Keane WF: Effects of reduced renal mass on tissue lipids and renal injury in hyperlipid-emic rats. Kidney Int 1989; 35: 40-47. (Pubitemid 19047422)
10. Siest G, Pillot T, Regis-Bailly A, Leininger-Muller B, Steinmetz J, Galteau MM, Visvikis S: Apolipoprotein E: an important gene and protein to follow in laboratory medicine. Clin Chem 1995; 41: 1068-1086.
11. Mahley RW: Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. Science 1988; 240: 622-630.
12. Chu AY, Parekh RS, Astor BC, Coresh J, Berthier-Schaad Y, Smith MW, Shuldiner AR Kao WH: Association of APOE poly-morphism with chronic kidney disease in a nationally representative sample: a Third National Health and Nutrition Examination Survey (NHANES III) Genetic Study. BMC Med Genet 2009; 10: 108.
13. Leiva E, Mujica V, Elematore I, Orrego R Diaz G, Prieto M, Arredondo M: Relation-ship between apolipoprotein E polymor-phism and nephropathy in type-2 diabetic patients. Diabetes Res Clin Pract 2007; 78: 196-201. (Pubitemid 47451528)
14. Boizel R, Benhamou PY, Corticelli P, Valenti K, Bosson JL, Halimi S: APOE polymor-phism and albuminuria in diabetes mellitus: a role for LDL in the development of ne-phropathy in NIDDM? Nephrol Dial Trans-plant 1998; 13: 72-75. (Pubitemid 28033582)
15. Adler AI, Stevens RJ, Manley SE, Bilous RW, Cull CA, Holman RR: Development and pro-gression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int 2003; 63: 225-232. (Pubitemid 35463925)
16. Araki S, Koya D, Makiishi T, Sugimoto T, Isono M, Kikkawa R, Kashiwagi A, Haneda M: APOE polymorphism and the progres-sion of diabetic nephropathy in Japanese subjects with type 2 diabetes: results of a pro-spective observational follow-up study. Dia-betes Care 2003; 26: 2416-2420. (Pubitemid 36993336)
17. Joss N, Jardine A, Gaffney D, Boulton-Jones JM: Influence of apolipoprotein E genotype on progression of diabetic nephropathy. Nephron 2005; 101:e127-e133.
18. Erdogan M, Eroglu Z, Biray C, Karadeniz M, Cetinkalp S, Kosova B, Gunduz C, Topcuo-glu N, Ozgen G, Yilmaz C: The relationship of the apolipoprotein E gene polymorphism Turkish type 2 diabetic patients with and without nephropathy. J Endocrinol Invest 2009; 32: 219-222.
19. Parving HH, Lewis JB, Ravid M, Remuzzi G, Hunsicker LG: Prevalence and risk factors for microalbuminuria in a referred cohort of type ii diabetic patients: a global perspective. Kidney Int 2006; 69: 2057-2063. (Pubitemid 43924271)
20. Hsieh MC, Lin SR, Yang YC, Chen HC, Lin JN, Shin SJ: Higher frequency of apolipopro-tein E2 allele in type 2 diabetic patients with nephropathy in Taiwan. J Nephrol 2002; 15: 368-373.
21. Bennet AM, Di Angelantonio E, Ye Z, Wens-ley F, Dahlin A, Ahlbom A, Keavney B, Col-lins R, Wiman B, de Faire U, Danesh J: As-sociation of apolipoprotein E genotypes with lipid levels and coronary risk. JAMA 2007; 298: 1300-1311. (Pubitemid 47443344)
22. Hsu CC, Kao WH, Coresh J, Pankow JS, Marsh-Manzi J, Boerwinkle E, Bray MS: Apolipoprotein E and progression of chronic kidney disease. JAMA 2005; 293: 2892-2899. (Pubitemid 41029143)
23. Kwon MK, Rhee SY, Chon S, Oh S, Woo JT, Kim SW, Kim JW, Kim YS, Jeong KH, Lee SH, Lee TW, Ihm CG: Association between apolipoprotein E genetic polymorphism and the development of diabetic nephropathy in type 2 diabetic patients. Diabetes Res Clin Pract 2007; 77(suppl 1):S228-S232. (Pubitemid 47212581)
24. Grone HJ, Walli A, Grone E, Niedmann P, Thiery J, Seidel D, Helmchen U: Induction of glomerulosclerosis by dietary lipids. A func-tional and morphologic study in the rat. Lab Invest 1989; 60: 433-446. (Pubitemid 19095960)
25. Sandhu S, Wiebe N, Fried LF, Tonelli M: Statins for improving renal outcomes: a me-ta-analysis. J Am Soc Nephrol 2006; 17: 2006-2016. (Pubitemid 44036185)
26. Frikke-Schmidt R, Nordestgaard BG, Ager-holm-Larsen B, Schnohr P, Tybjaerg-Hansen A: Context-dependent and invariant associ-ations between lipids, lipoproteins, and apo-lipoproteins and apolipoprotein E genotype. J Lipid Res 2000; 41: 1812-1822.
27. Bednarska-Makaruk M, Broda G, Kurjata P, Rodo M, Roszczynko M, Rywik S, Wehr H: Apolipoprotein E genotype, lipid levels and coronary heart disease in a Polish popula-tion group. Eur J Epidemiol 2001; 17: 789-792. (Pubitemid 34602348)
28. Dietrich M, Hu Y, Block G, Olano E, Packer L, Morrow JD, Hudes M, Abdukeyum G, Rimbach G, Minihane AM: Associations be-tween apolipoprotein E genotype and circu-lating F2-isoprostane levels in humans. Lip-ids 2005; 40: 329-334. (Pubitemid 40770942)
29. Brown CM, Wright E, Colton CA, Sullivan PM, Laskowitz DT, Vitek MP: Apolipopro-tein E isoform-mediated regulation of nitric oxide release. Free Radic Biol Med 2002; 32: 1071-1075. (Pubitemid 34603344)
30. Kimura H, Suzuki Y, Gejyo F, Karasawa R, Miyazaki R, Suzuki S, Arakawa M: Apolipo-protein E4 reduces risk of diabetic nephrop-athy in patients with NIDDM. Am J Kidney Dis 1998; 31: 666-673. (Pubitemid 28158008)